Novartis has been granted a patent for a compound of Formula (I) that shows promise in treating diseases caused by viral infections. The compound or its salt is claimed for pharmaceutical use. GlobalData’s report on Novartis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Novartis, Cancer treatment biomarkers was a key innovation area identified from patents. Novartis's grant share as of May 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US12012417B2) discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof, with specific variations outlined in the claims. These variations include different substituents for R2 and L, as well as specific options for R3. The patent also covers compounds of formula (IA) and (IC), along with pharmaceutical compositions comprising these compounds and methods for treating viral infections, specifically dengue virus.
The patent claims encompass a range of compounds and their pharmaceutically acceptable salts, offering potential therapeutic options for diseases caused by viral infections, particularly dengue virus. The inclusion of specific substituents and variations in the compounds allows for a tailored approach to treatment. Additionally, the patent extends to pharmaceutical compositions containing these compounds, either alone or in combination with other pharmaceutical agents, enhancing the scope of potential treatments. The method outlined for treating viral infections provides a clear pathway for administering these compounds to individuals in need, highlighting the practical application of the patented compounds in a clinical setting.
To know more about GlobalData’s detailed insights on Novartis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
